STAT3-Targeting Oligonucleotides for Tumor Microenvironment Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, often lead to multidrug resistance and tumor relapse due to the role of tumor microenvironment (TME) components, including normal cells that contribute to drug resistance and tumor progression.
Innovation Solution
The use of oligonucleotides targeting STAT3 mRNA, combined with a PD-L1 inhibitor, to synergistically reduce tumor volume and induce anti-tumor memory responses in various tumor microenvironments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used as the leading cancer therapy, then tumor cells can be killed initially, but multidrug resistance develops leading to tumor relapse and limited therapeutic options
Solution Approach 1:
The patent segments the cancer treatment approach by targeting not only tumor cells but also the tumor microenvironment components (normal cells, immune cells, stromal cells) that contribute to drug resistance. This multi-target strategy divides the complex problem of multidrug resistance into manageable components, each addressed by specific oligonucleotide therapies against STAT3 and other TME factors.
Solution Approach 2:
The patent employs preliminary action by using oligonucleotides to pre-condition the tumor microenvironment before chemotherapy administration. By downregulating STAT3 and other resistance-related genes in advance, the treatment sensitizes tumor cells and TME components to subsequent chemotherapy, preventing the development of multidrug resistance.
2Measurement precision
If cancer research focuses only on tumor cells, then tumor-specific targets can be identified, but the role of tumor microenvironment and normal cells in tumor progression and drug resistance is overlooked
Solution Approach 1:
The patent applies universality by developing oligonucleotide therapies that simultaneously address multiple functions within the tumor microenvironment. A single STAT3-targeting oligonucleotide can affect tumor cells, immune cells, and stromal cells, providing comprehensive coverage of TME-related processes including angiogenesis, immune suppression, and drug resistance.
Solution Approach 2:
The patent transitions from a one-dimensional focus on tumor cells to a multi-dimensional approach by incorporating TME components into the therapeutic target list. This dimensional expansion includes targeting immune cells, fibroblasts, endothelial cells, and extracellular matrix, creating a holistic treatment strategy that addresses the full complexity of cancer progression.
3Reliability
If a combination of STAT3 oligonucleotide and PD-L1 inhibitor is used, then synergistic anti-tumor efficacy is achieved, but treatment complexity increases
Solution Approach 1:
The patent merges two distinct therapeutic mechanisms into a unified treatment regimen: STAT3 downregulation via oligonucleotides and PD-L1 inhibition via antibodies. This combination creates synergistic effects where STAT3 suppression enhances immune cell infiltration and function, while PD-L1 blockade releases immune checkpoints, together producing amplified anti-tumor immunity that overcomes the complexity through mechanistic integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination therapy effectively reduces tumor volume, induces immune responses, and prevents tumor re-growth, demonstrating synergistic anti-tumor efficacy.
Implementation Method 1
the antisense strand has a region of complementarity to a target sequence of STAT3
Data Source
AI summary
The subject matter disclosed herein is directed to modulating STAT3 gene expression using siRNA compositions and methods directed to affecting key cell populations supporting the growth and metastasis of cancer to affect the beneficial treatment, remission or removal of the underlying tumor in a patient.